Gensight biologics announces the filing of its 2024 universal registration document

Paris--(business wire)--regulatory news: gensight biologics (euronext: sight, isin: fr0013183985, pea-pme eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the filing on april 7, 2025 of its 2024 universal registration document (urd) in english with the french market authority (autoritÉs des marchÉs financiers, or amf). the universal registration document inclu.
UVV Ratings Summary
UVV Quant Ranking